Many multinational companies have chosen to forgo establishing production facilities in Indonesia or have even shuttered their facilities, as did Janssen-Cilag. With the recent 10/10 decree,…
In Conversation
The acquisition of IVAX in 2006 was decisive to establish Teva as the number one generic producer worldwide and further consolidate the company in the German…
You have recently taken over the position as head of AstraZeneca in South Korea, after several years working in China. What view did you have of…
Astellas has been present in the German market for almost two decades through Yamanouchi and Fujisawa. But since 2005 it gained a new identity thanks to…
What is KHIDI’s role in supporting the development of the Korean health industry? KHIDI performs three major roles in supporting the Korean health industry, which includes…
Please introduce Handok Pharmaceuticals to our readers, and in particular how it has evolved through partnerships with different multinational companies throughout its history. Handok has developed…
When you were appointed General Director of the Agenzia Italiana del Farmaco (AIFA) in 2007, the dedicated Investigation Commission highlighted the need for an in-depth reorganization…
You have been in South Korea for several months, following some time as Merck’s President in Pakistan. In your opinion, what do you find as the…
When you became President of Sankyo Pharma Italy in 2003 one of your objectives was to maximize sales of the existing portfolio- and the company’s sales…
The Indonesian pharmaceutical market has gone through a series of developing phases which have ultimately led the domestic industry to gain the majority of the market…
Cytonet is today Germany’s largest cell therapy enterprise. However, it went through many transformations since its spin-off from Roche Diagnostics in 2000. Could you briefly introduce…
You have recently been appointed as General Manager of Servier in South Korea, after coming from several years working in Europe. What perception did you have…
